Related Experiment Video
Updated: Jul 6, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin
Yaakov Nahmias1, Jonathan Goldwasser, Monica Casali
1Center for Engineering in Medicine, Shriners Burns Hospital, Boston, MA, USA. ynahmias@partners.org
Insights
The grapefruit flavonoid naringenin significantly reduces Hepatitis C virus (HCV) secretion by inhibiting very low density lipoprotein (vLDL) assembly and release. This offers a promising new therapeutic strategy for treating chronic liver disease caused by HCV infection.
Area of Science:
- Hepatology
- Virology
- Biochemistry
Background:
- Hepatitis C virus (HCV) is a major global cause of chronic liver disease.
- HCV interacts with host lipid metabolism and lipoproteins for its lifecycle.
- The mechanism of HCV secretion involves association with very low density lipoprotein (vLDL).
Purpose of the Study:
- To investigate the role of very low density lipoprotein (vLDL) in Hepatitis C virus (HCV) secretion.
- To evaluate the potential of naringenin, a grapefruit flavonoid, as an antiviral agent against HCV.
Main Methods:
- Investigated HCV secretion via a Golgi-dependent mechanism linked to vLDL.
- Utilized apolipoprotein B (ApoB) messenger RNA silencing to assess its impact on HCV secretion.
- Examined the effect of naringenin on vLDL secretion, microsomal triglyceride transfer protein (MTP) activity, and key lipid-related gene transcription in HCV-infected cells.
Main Results:
- Silencing ApoB reduced secretion of both ApoB-100 and HCV by 70%.
- Naringenin inhibited MTP activity and the transcription of HMGCR and ACAT2.
- Naringenin treatment decreased HCV secretion by 80% at non-toxic concentrations in hepatocytes and mice.
Conclusions:
- HCV is secreted via a vLDL-dependent pathway.
- Naringenin effectively inhibits HCV secretion by targeting lipid metabolism pathways.
- Naringenin represents a potential novel therapeutic for Hepatitis C virus infection.
Unlabelled:
Hepatitis C virus (HCV) infects over 3% of the world population and is the leading cause of chronic liver disease worldwide. HCV has long been known to associate with circulating lipoproteins, and its interactions with the cholesterol and lipid pathways have been recently described. In this work, we demonstrate that HCV is actively secreted by infected cells through a Golgi-dependent mechanism while bound to very low density lipoprotein (vLDL). Silencing apolipoprotein B (ApoB) messenger RNA in infected cells causes a 70% reduction in the secretion of both ApoB-100 and HCV. More importantly, we demonstrate that the grapefruit flavonoid naringenin, previously shown to inhibit vLDL secretion both in vivo and in vitro, inhibits the microsomal triglyceride transfer protein activity as well as the transcription of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase and acyl-coenzyme A:cholesterol acyltransferase 2 in infected cells. Stimulation with naringenin reduces HCV secretion in infected cells by 80%. Moreover, we find that naringenin is effective at concentrations that are an order of magnitude below the toxic threshold in primary human hepatocytes and in mice.
Conclusion:
These results suggest a novel therapeutic approach for the treatment of HCV infection.
Related Concept Videos
Hepatitis
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Viruses with RNA Genomes

